Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
Feb 1, 2004 → Dec 1, 2005
NCT ID
NCT01084265About Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)
Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG) is a phase 3 stage product being developed by Merck for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT01084265. Target conditions include Hypogonadism.
What happened to similar drugs?
6 of 18 similar drugs in Hypogonadism were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01084265 | Phase 3 | Completed |
Competing Products
20 competing products in Hypogonadism